{"name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","slug":"shanghai-jiaolian-drug-research-and-development-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"B007","genericName":"B007","slug":"b007","indication":"Advanced solid tumors with PI3K/AKT pathway alterations","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"B013","genericName":"B013","slug":"b013","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"B007","genericName":"B007","slug":"b007","phase":"phase_2","mechanism":"B007 is a small molecule that targets the PI3K/AKT signaling pathway.","indications":["Advanced solid tumors with PI3K/AKT pathway alterations"],"catalyst":""},{"name":"B013","genericName":"B013","slug":"b013","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPUU9GX21ndGt0WW1pWjVVOUZld0gtM09LcC1BLURCMjgxckI0VGV4MXduQTJ4eDNGTkN1SU8wcnBkTlFfeW5rMFlJU1FabUVTVFE1eC12czZZMzhKQzdvVU1ORmZSTjhaV3NzaHU3Rjl3WS1taXQ4dHJCV1NMb2dBVmphRldfcUpWOFRxZG9pOElaS1RmR1VtTw?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"Breast Cancer Clinical Trial Gains Momentum: 250+ Companies - openPR.com","headline":"Breast Cancer Clinical Trial Gains Momentum: 250+ Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPRTBaMkhQdFZ5T2lCWEpjZnBRSFIzMGIxVUtsM1BvZmJHcUpZOGtSWmhSSVJhNFBjelAtN2tpbzJWZ0JTYlFUazNNbWFKcUZVVU9yTFJuTDhXbHBZQ0JjVEhhQWJobENFek1sWG82Ny0xNHRaLWhQMjVKSEtfa1Q4NEY1Z2x6cGpVM0VTN2pjbE1pWHRJVjJaSmhTOEZLYmdJR0QzWUwxV245OXdRbFQ4a1A0d1FHVTQ3d2NXRmZqanhxQjNTRmVhSzJFdncwWk40TzRUX1lNN0NxRzROM1h4ZXVDV1JOel9OT01BRQ?oc=5","date":"2026-03-16","type":"pipeline","source":"PR Newswire","summary":"Neuromyelitis Optica Spectrum Disorder Market Poised for Robust Expansion Through 2036 | DelveInsight - PR Newswire","headline":"Neuromyelitis Optica Spectrum Disorder Market Poised for Robust Expansion Through 2036 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQQlAzMnRCdzVmcUFpdmF3dXNnQUtvbFQ0cFc5My1LUnJLRG91OWdSaklfVW5JUmRWTG5fOEF2YUFiVWZUOXBRamZrTUxKazBCZ3FUTEpBLUxFRDVyT0p0YjZkVTQzVk9hdWJtNXlPcnFmWUtHVWFHY2xtQjN0QWc4NEpYemZ3TGwyOUpNV2o4YUJWRDI4eTFXZDY4TXE3bi1XcFVjYWRCc1VUUDQtMUd1UGllaFFkS21Od2FtU0ZoU05XZWk0QXpDd2tVejE4aFp5MEhRYnhVVDhIMlp2NTRPSjNVMk02WVFpZzh6NzdzN2pXVWVFRXR5UmIySTA0bXdMZ3pGMWc1WEYzZGZXLTYyd2RneTIwWTBJZ0R4eQ?oc=5","date":"2025-07-29","type":"pipeline","source":"PR Newswire","summary":"Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}